おすすめの製品
グレード
pharmaceutical primary standard
APIファミリー
misoprostol
メーカー／製品名
EDQM
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
保管温度
−20°C
SMILES記法
CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
InChI
1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
InChI Key
OJLOPKGSLYJEMD-URPKTTJQSA-N
遺伝子情報
human ... PTGER3(5733)
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
アプリケーション
Misoprostol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生物化学的／生理学的作用
素早く脱エステル化して活性な「ミソプロストール酸」になるPGE1類似化合物プロドラッグです。NSAID誘導消化器系潰瘍の予防、免疫系カスケードの制御、血小板活性化因子(PAF)の阻害、エタノールおよびアセトアミノフェン誘導肝毒性および肝炎の治療、負傷後の軟骨修復の促進など、極めて幅広い治療効果が挙げられています。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
その他情報
Sales restrictions may apply.
シグナルワード
Danger
危険有害性情報
危険有害性の分類
Acute Tox. 3 Oral - Repr. 1B
保管分類コード
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
最新バージョンのいずれかを選択してください：
Amanda Selk et al.
Obstetrics and gynecology, 118(4), 941-949 (2011-09-22)
To estimate the benefits and harms of misoprostol use for cervical dilation in patients undergoing operative hysteroscopy. We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (from inception to February 2011). We also searched trial registries, other
C W Ho et al.
Alimentary pharmacology & therapeutics, 37(8), 819-824 (2013-02-26)
Poor adherence to gastroprotective agents (GPAs) is common among users of nonsteroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (ASA). There are little data on the utilization of GPAs among NSAID and ASA users complicated by ulcer bleeding. To study the
Deborah Bartz et al.
Obstetrics and gynecology, 122(1), 57-63 (2013-06-08)
To compare the efficacy and acceptability of buccal misoprostol or a synthetic osmotic cervical dilator for cervical preparation before same-day late first-trimester and early second-trimester surgical abortion. In this randomized, double-blind trial, we compared 400 micrograms of buccal misoprostol with
Heleen J van Beekhuizen et al.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 122(3), 234-237 (2013-06-25)
To evaluate the efficacy and safety of misoprostol among patients with retained placenta in a low-resource setting. A prospective, multicenter, randomized, double-blind, placebo-controlled trial was carried out in Tanzania between April 2008 and November 2011. It included patients who delivered
N P Polyzos et al.
Human reproduction update, 18(4), 393-404 (2012-05-01)
Although several randomized controlled trials (RCTs) have examined the effect of misoprostol prior to hysteroscopy for cervical dilatation, no solid conclusion has been reached. We therefore set out to perform a meta-analysis of RCTs. We searched MEDLINE, the ISI Web
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）